IMNN Stock Summary and Trading Ideas (Imunon | NASDAQ:IMNN)

Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective, and durable responses across various human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. Its clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer that has completed Phase II clinical studies. Additionally, the Company has entered a first-in-human study of its COVID-19 booster vaccine (IMNN-101).

Imunon trades on the NASDAQ stock market under the symbol IMNN.

As of December 31, 2025, IMNN stock price climbed to $3.81 with 97,129 million shares trading.

IMNN has a beta of -1.63, meaning it tends to be less sensitive to market movements. IMNN has a correlation of 0.03 to the broad based SPY ETF.

IMNN has a market cap of $11.70 million. This is considered a Sub-Micro Cap stock.

In the last 3 years, IMNN traded as high as $41.40 and as low as $2.99.

The top ETF exchange traded funds that IMNN belongs to (by Net Assets): VTI, VXF.

IMNN has underperformed the market in the last year with a price return of -59.3% while the SPY ETF gained +17.2%. IMNN has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -25.7% and -1.8%, respectively, while the SPY returned +2.7% and +0.7%, respectively.

IMNN support price is $3.28 and resistance is $3.68 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that IMNN shares will trade within this expected range on the day.